Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Amniotic Membrane to Decrease Post Operative Atrial Fibrillation After CABG
NCT04130061Phase 1Completed
- Sponsor
- University of Utah
- Start
- Oct 2019
- Primary completion
- Jun 2021
- Modality
- Tissue Cells, Hydrogel Systems
- Countries
- 1
01
Overview
Phase 1, randomised trial of biological amniotic membrane in Atrial fibrillation (AFib) (2 arms), sponsored by University of Utah. Primary endpoints: Number of Participants With Adverse Events at 1 month, Incidence of Post-Operative Atrial Fibrillation at 1 month and 8 more. Started Oct 2019; status: completed.
02
Drugs
biological amniotic membrane
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT04130061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04130061.